Slide 1: Bactiguard Year-end presentation
1 Bactiguard Year-end presentation February 9, 2017
Slide 2: At war against healthcare associated infections
2 At war against healthcare associated infections The Economist May 2016 • First reported U.S. case of bacterial infection resistant to last resort antibiotic • Superbugs now present on all continents
Slide 3: Source link: scmp.com article
Source link: http://www.scmp.com/magazines/post-magazine/long-reads/article/2048942/why- china-heart-fight-head-antibiotic-apocalypse
Slide 4: Woman dies of bug resistant to all antibiotics after India trip
es od Woman dies of bug resistant to all antibiotics after India trip NEW DELHI: An American woman who travelled to India died from an infection resistant to all avail- able antibiotics, health officials said this week, raising new con- and had been hospitalised in India with Packuped leg bones, the
Slide 5: The global challenge
5 The global challenge Professor Hans Rosling 1948 - 2017 ” Multiresistant bacteria is a greater threat to mankind than climate change.” Professor Hans Rosling, Karolinska Institute
Slide 6: Bloodstream infections most common type of HAI in European pediatric ICUs
6 Bloodstream infections most common type of HAI in European pediatric ICUs • 1 in 6 children in ICUs were infected • 1 in 10 babies were infected in Neonatal ICUs • 770 infections in 726 children • Bloodstream infections were the most common: 45% of infections
Slide 7: Key Priorities 2016
7 Key Priorities 2016 Drive sales of our own product portfolio Bactiguard Infection Prevention Develop new license businesses Secure long-term refinancing
Slide 8: Achievements in 2016
8 Achievements in 2016 BIP volume more than doubled Breakthrough in China and India Expanding European presence Progress in our home market Sweden Strengthened clinical evidence Product portfolio tailored to ICUs Tools supporting new standards of care for prevention of HAI • Bactiguard
Slide 9: Highlights in Q4 2016 and early 2017
9 Highlights in Q4 2016 and early 2017 Major increase in deliveries of BIP products Repeat order from China of 100,000 catheters delivered Entering partnership in Germany Stable revenues from C.R. Bard New distributor Egypt New clinical study confirms reduced infections in ICU Bond loan
Slide 10: Supplied products
Delivered products Financial overview 10 Supplied products • 134,000 BIP products delivered in Q4 2016 compared to 74,000 during Q4 2015, an increase by 81 % • For the full year 2016, 418,000 BIP products were delivered compared to 152,000 full year 2015, an increase by 175 %
Slide 11: Market update
11 Market update Focus on select markets and building recurring volume Europe • Expanding presence • Strong foothold in DACH region • Focus on adding new sizeable market • Strengthening the team • Moving ahead in Sweden CHINA MEA • Major deliveries • 2016 below expectations • Training, sales activit
Slide 12: Licensing business
12 Licensing business C.R. Bard • Successful partnership since 1995 • Bactiguard coated Foley catheters for the US, Japan and UK/Ireland • More than 160 million catheters sold to date • Generating stable annual revenues Vigilenz Medical Devices • Bactiguard coated orthopaedic implants for the Asean
Slide 13: New license agreement and therapeutic application
13 New license agreement and therapeutic application Advanced Bactiguard-coated vascular injection catheters Aimed at delivering high dose, locally targeted therapies to damaged tissue, in critical areas of the body Coating reduces risk of infections, thrombosis and allergic reactions for crit
Slide 14: The Extroducer micro catheter
14 The Extroducer micro catheter Unique micro catheter, the width of a human hair Designed to navigate to any organ via blood vessels Can be implemented in existing hospital catheterization facilities Needle tip designed to puncture the blood vessel wall, deliver drugs and withdraw without c
Slide 15: The Extroducer micro catheter
15 The Extroducer micro catheter Where it can go: What it can deliver Brain • Cells • Biologic therapies • High dose chemotherapy • Repurposed drugs Heart Liver Pancreas Kidney
Slide 16: Financial highlights
16 Financial highlights Highlights Fourth quarter (Oct-Dec 2016) • Revenues of MSEK 33.6 (20.6), plus 63% (higher License and BIP revenues) • EBITDA of MSEK 4.5 (-6.1), 14% margin Full year (Jan-Dec 2016) =Additional order • Revenues of MSEK 128.3 (138.5), C.R. Bard Previous year included effects of
Slide 17: Revenue streams
17 Revenue streams Two revenue streams in the income statement License BIP portfolio Bard (sales since 1995) and BIP Foley BIP ETT BIP CVC Vigilenz license deals 1 2 License BIP revenue From a product perspective Bactiguard has two lines of business; Licenses and the BIP portfolio, acknowledged in t
Slide 18: Income distribution
Revenue distribution Financial overview 18 Income distribution Oct-Dec Oct-Dec Full year MSEK 2016 2015 2016 License revenues 25,9 15,9 103,0 Sales of BIP products 5,7 2,4 15,8 Other revenue 2,0 2,2 9,6 Total Revenues 33,6 20,6 128,3
Slide 19: License revenues from C.R. Bard
License revenues from C.R. Bard Financial overview 19 License revenues (SEKm) Q1 Q2 H1 Q3 Q4 Full year 2013 21,6 19,3 40,9 21,3 20,5 82,7 2014 22,5 22,8 45,3 24,3 20,2 89,7 2015 26,8 25,8 52,6 56,8 15,9 125,3 Of which currency effect, 2016 22,8 27,2 50,0 27,1 25,9 103,0 MSEK +1.6 Of which currency e
Slide 20: Key figures
Key figures Financial overview 20 Key figures Oct-Dec Oct-Dec Full year Full year • EBITDA (Q4) MSEK 4.5 Key figures 2016 2015 2016 2015 (-6.1), 14% margin Revenues, SEKm 33,6 20,6 128,3 138,5 EBITDA, SEKm 4,5 -6,1 15,1 20,2 • EBITDA (full year) MSEK 15.1 (20.2), 12% margin EBITDA margin, % 14% -30%
Slide 21: Financial flexibility and strength
Financial flexibility and strength Financial overview 21 Refinancing of bond loan • Bond loan matured on 12 Dec, 2016. Outstanding nominal value of MSEK 138 and accrued interest paid in full. • Refinancing solution: • Bank loan: MSEK 100, maturing 31 Dec, 2017 • Loan major shareholders: MSEK 50, mat
Slide 22: Financial targets
22 Financial targets • Average sales growth of 20% per annum for a 5-year period, with 2015 (adjusted for the additional order from C.R. Bard) as the base year – starting point MSEK 118.5 • EBITDA margin of at least 30% at the end of the 5-year period • Equity ratio of at least 30% • Over time uphol
Slide 23: Concluding remarks
23 Concluding remarks BIP volume more than doubled in 2016 Breakthrough in China and India Expanding in Europe and the Middle East Intensive care focus, combining all three products License agreement in new therapeutic area Well positioned for growth both in BIP portfolio and license bus
Slide 24: Priorities for 2017
24 Priorities for 2017 Double sales of our own product portfolio Develop new licensing agreements Expansion with cost control Long term financing solution Close in on our long-term financial targets of 20% growth and 30% EBITDA margin
Slide 25: More information is available at www.bactiguard.se
25 More information is available at www.bactiguard.se For questions and additional information, please contact: Christian Kinch, CEO: +46 8 440 58 80 christian.kinch@bactiguard.se Fredrik Järrsten, CFO: +46 725 500 089 fredrik.jarrsten@bactiguard.se Cecilia Edström, SVP Sales & New Business: +46 725
Slide 26: Questions
26 Bactiguard At war against hospital acquired infection Questions